LBO — RENOWN SOUTH MEADOWS MED CTR
IRR: 24.6% | MOIC: 3.01x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
24.6%
IRR
3.01x
MOIC
$37.3M
Entry EV
$75.4M
Exit EV
$19.2M
Equity Invested
Sources & Uses
S&UTotal · $37.3M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $14.5M | 38.8% | |
| Sub Debt | $3.6M | 9.7% | |
| Equity | $19.2M | 51.5% | |
| Enterprise Value | $36.2M | 97.1% | |
| Transaction Fees | $1.1M | 2.9% | |
| Total Uses | $37.3M | 100.0% |
Interpretation
INTAt 3.01x MOIC and 24.6% IRR over 5 years, this deal exceeds the typical 20% hurdle — strong candidate.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $7.2M |
| Exit Ev | $75.4M |
| Net Debt At Exit | $17.6M |
| Equity At Exit | $57.8M |
| Equity Invested | $19.2M |
| Total Value Created | $38.6M |
| Value From Growth | $37.3M |
| Value From Multiple | $1.8M |
| Value From Deleveraging | $0.5M |